The European end of a global catalyst season
Most of the headline oncology deadlines this autumn are American. The European regulatory news in our dossier is already concrete. On 24 July 2026 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorisation of Gilead's Trodelvy plus Keytruda for PD-(L)1-positive first-line metastatic triple-negative breast cancer.1 Gilead framed a second first-line approval as establishing Trodelvy as a backbone therapy across PD-L1 status in the European Union.1 The company says the ASCENT-04/KEYNOTE-D19 trial showed a highly statistically significant reduction in the risk of disease progression or death.1 That is Gilead's characterisation. The dossier does not give the underlying figures, and a CHMP opinion is a recommendation, not a final authorisation.
Evandro de Azambuja said: "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1." He added: "This positive opinion is welcome news for our patients and the entire clinical community."1
A second European data point comes from commercial medtech. Novocure, which datelines its results from Baar, Switzerland, reported second-quarter 2026 net revenues of $184 million, up 16% year-over-year, with 18% global active-patient growth.2 It received a CE Mark for Optune Pax for locally advanced pancreatic cancer, and Germany is the first EU market to launch. More than 280 patients were on Optune Pax as of 30 June 2026.2 Frank Leonard called it "our strongest quarter to date, with record net revenues and active patients on therapy."2
The calendar that matters, and what has already happened
Three dated events frame the rest of the year, and one has already moved.
Summit's Biologics License Application for ivonescimab, based on the HARMONi trial, carries a US FDA PDUFA goal date of 14 November 2026.3 That is a US decision, but it is the first regulatory test of the bispecific antibody that the combination story rests on. Moderna and Merck plan to present detailed intismeran results, their personalised mRNA cancer vaccine, at ESMO on 24 October. They also plan to engage with regulators on potential filings.4 ESMO is a European medical society meeting, so the first detailed look at this vaccine will come before a European audience. Note the wording: "potential filings". Nothing in the dossier says a filing has been made, in the EU or anywhere else.
The third catalyst has arrived. The dossier's topline for the EXCALIBER-RRMM Phase 3 is dated 8 October 2026. ZDd showed a statistically significant improvement in the dual-primary endpoint of progression-free survival, with a median of 42 months against 20 months for DVd (hazard ratio 0.49, p<0.000001). That is a 51% reduction in the risk of progression or death, with median follow-up of 23 months and safety consistent with prior findings.5 Median follow-up of 23 months is shorter than either arm's median progression-free survival. The 42-month figure is therefore an estimate of a time many patients have not yet reached. The dossier does not expand the ZDd and DVd abbreviations, and we do not guess at them.
On 2 October, Summit announced a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab with Datroway across multiple solid tumour settings, intending to include breast and lung cancer.6 This is the bispecific-plus-ADC pairing in our headline. It is a plan to run trials, not evidence that the combination works.
What the checked numbers say about Merck
Merck is a US company, headquartered in Rahway, New Jersey. We use it as the dossier's one SEC-verified balance sheet, to show what a big oncology developer's finances look like while these catalysts approach. Every figure below is canonical, drawn from SEC filings.
Capital spending is falling. Merck's capex was $3.863 billion in fiscal 2023 and $3.372 billion in 2024, then rose to $4.112 billion in 2025.7 In the first quarter it ran $861 million in 2024 and $1.328 billion in 2025, then fell to $991 million in 2026, about a quarter lower than a year earlier.7 Our filings do not say why. We do not read it as a verdict on oncology.
Cash is volatile. Merck held $6.841 billion at the end of fiscal 2023, $13.242 billion at the end of 2024 and $14.565 billion at the end of 2025.8 Within the last twelve months of data it peaked at $18.169 billion in the third quarter of 2025, then stood at $5.327 billion in the first quarter of 2026 and $6.849 billion in the second.8 That is a gap of roughly $11 billion between Q3 2025 and Q2 2026, our arithmetic from the filed figures. To picture the scale, the swing is nearly three times Merck's entire full-year 2025 capital spending of $4.112 billion.7 The filings in our dossier do not say what drove the drop, so we do not attribute it to acquisitions, dividends or anything else. Cash on a quarter-end date is a snapshot, and company treasuries move it for many reasons.
The cost of making the product is rising. Cost of revenue was $4.195 billion in the first quarter of 2026, against $3.419 billion a year earlier.9 In the second quarter it was $4.395 billion against $3.557 billion.9 Both are roughly 23% higher. Full-year 2025 cost of revenue was $16.382 billion, against $15.193 billion in 2024.9 We have no revenue figures in the dossier, so we cannot say whether this is growth or margin pressure.
AstraZeneca's AI pitch, and why we flag its source
AstraZeneca's Puja Sapra describes a 'lab of the future' in which "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."10 She says proprietary data is the differentiator: "Data is our differentiator."10 She is also candid about the weak point: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."10 And she stresses that "human oversight remains at the heart of this approach".10
These are the company's own statements of intent, published in MIT Technology Review, not results. We also have a measured reliability warning. In our substrate, none of the 11 claims checked from that source held up. That is a small sample and says little about the quality of the whole publication. But it is a reason to read the AI claims as aspiration, not as proof of faster timelines, and no discovery-time saving is quantified anywhere in the dossier.
The small-company squeeze
Not everyone has Merck's cash. ADC Therapeutics SA said a workforce reduction is "projected to deliver $10 million in annualised cost savings", and that it "maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations".11 This is the company's own account, reported in a weekly sector roundup. On the other side of the divide, Telix has dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx for relapsed or recurrent clear cell renal cell carcinoma. It describes this as the first radiopharmaceutical therapy to enter Phase 3 development for that cancer.12 Neither company's news changes the picture on its own. Together they show an uneven field: the commercial players are reporting records, while smaller developers are trimming costs to stretch their funding.
How far to trust this
The sources are not equal. Our measured reliability for the wire-service documents is 56% of 4,956 checked claims held up for the Gilead and Novocure items, 31% of 2,928 for the Telix item and 45% of 520 for the weekly roundup.1,2,11,12 In plain terms, a large share of claims from these feeds do not hold up when checked. We have leaned on dated, attributable statements and SEC-sourced numbers, and we label company claims as company claims.
What to watch
- 24 October: the ESMO presentation of detailed intismeran results, and whether Moderna and Merck say anything concrete about regulatory filings.4
- 14 November: the FDA decision date for the ivonescimab BLA.3
- EU follow-through: the European Commission's final decision on Trodelvy plus Keytruda following the CHMP opinion, and how fast Optune Pax rolls out beyond Germany.1,2
- Merck's next filing: whether cash and capex settle or keep swinging.7,8
